ClinicalTrials.Veeva

Menu
M

Marietta Eye Clinic | Marietta, GA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Abicipar Pegol
Sirolimus
DE-109
THR-149
Fluocinolone Acetonide
Aflibercept
RG7774
Triamcinolone Acetonide
ONL1204
JNJ-81201887

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

6 of 21 total trials
Locations recently updated

A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

The purpose of this study is to evaluate change in geographic atrophy (GA) lesion growth of eyes treated with JNJ-81201887 compared to sham control.

Enrolling
Geographic Atrophy
Drug: Triamcinolone
Other: Sham Procedure

Researchers are looking for a better way to treat people who have macular edema secondary to retinal vein occlusion (RVO).In people with RVO, a blood...

Enrolling
Macular Edema Secondary to Retinal Vein Occlusion
Drug: Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_2 mg
Drug: Sham

This is a conventional efficacy trial to validate the results from previous clinical trials for younger children; the 12-month efficacy results will...

Enrolling
Myopia
Myopia Progression
Device: Single vision, impact-resistant spectacle lenses; Test Arm
Device: Single vision, impact-resistant spectacle lenses; Control Arm

This randomized trial will evaluate the effect of fenofibrate compared with placebo for prevention of diabetic retinopathy (DR) worsening through 6 y...

Enrolling
Diabetic Retinopathy
Other: Placebo
Drug: Fenofibrate

A study to evaluate the safety and efficacy of YUTIQ® 0.18 mg intravitreal implant for the management of chronic non-infectious posterior segment uve...

Active, not recruiting
Uveitis, Posterior
Drug: Fluocinolone Acetonide Intravitreal Implant 0.18 mg

The VOYAGE trial will assess diabetic retinopathy severity scale (DRSS) levels, through 112 weeks, while being managed with aflibercept as needed, am...

Active, not recruiting
Diabetic Retinopathy
Drug: Aflibercept Injection

Trial sponsors

C
Jaeb Center for Health Research logo
A
Allergan logo
Bayer logo
Janssen (J&J Innovative Medicine) logo
O
Oxurion logo
Roche logo
S

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems